Lapatinib - Wikipedia, the free encyclopedia
Lapatinib or lapatinib ditosylate (Tykerb / Tyverb, GSK) is an orally active chemotherapeutic drug treatment for solid tumours such as breast cancer. [1]
Breast cancer treatment - Wikipedia, the free encyclopedia
lapatinib(TykerB) Kinase inhibitor: NeuVax; dHER2; MVF-HER-2; Vaccine: NeuVax is a HER2/neu peptide-based T-cell immunotherapy aimed at preventing disease recurrence and prolonging survival ...
Register for FREE
Although Tykerb offers patients a well-tolerated, conveniently administered alternative to intravenous (IV) therapy, oncologists are not yet ready to use Tykerb.
Tykerb TARGETING TUMORS
US FDA has approved Tykerb (lapatinib, manufactured by GlaxoSmithKline) in combination therapy with Xeloda (capectabine, manufactured by Roche) for treating HER2 positive, advanced ...
Lapatinib Delays HER2-Positive Breast Cancer - National Cancer ...
Lapatinib (Tykerb®) Plus Capecitabine Delays Progression of HER2-Positive Breast Cancer. Key Words. Breast cancer, HER2, lapatinib (Tykerb®), trastuzumab (Herceptin®).
Tykerb - Lapatinib - Targeted Biologic Therapy - Description of Tykerb
Tykerb (lapatinib) is a targeted biologic therapy given as treatment for HER2 positive metastatic breast cancer. Tykerb can be taken with Xeloda, another oral chemotherapy drug ...
tykerb tablets prescribing information
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TYKERB safely and effectively. See full prescribing information for TYKERB ...
TYKERB® (Lapatinib) Tablets FACT SHEET
TYKERB ® (Lapatinib) Tablets FACT SHEET What is Tykerb? æ A small molecule, dual inhibitor of EGFR (ErbB1) and HER2 (ErbB2) discovered and developed by GSK as an oral therapy ...
Tykerb
Tykerb is a drug licensed to treat metastatic breast cancer that has not responded to other treatments. This eMedTV page describes the effects of Tykerb, explains what to know ...
Tykerb, Tykerb Drug - FierceBiotech
Drug: Tykerb (lapatinib) Indication: Metastatic breast cancer Company: GlaxoSmithKline Approval Date: March 13, 2007 Scoop: The FDA gave its approval to Tykerb for metastatic ...
